{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:45:52Z","timestamp":1788306352583,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T00:00:00Z","timestamp":1589068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.thromres.2020.05.005","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T09:31:59Z","timestamp":1589189519000},"page":"52-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Pharmacokinetics for haemophilia treaters: Meaning of PK parameters, interpretation pitfalls, and use in the clinic"],"prefix":"10.1016","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7134-0713","authenticated-orcid":false,"given":"Xavier","family":"Delavenne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesim","family":"Dargaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9585","key":"10.1016\/j.thromres.2020.05.005_bb0005","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0140-6736(07)61199-4","article-title":"Coagulation factor concentrates: past, present, and future","volume":"370","author":"Key","year":"2007","journal-title":"Lancet."},{"key":"10.1016\/j.thromres.2020.05.005_bb0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.thromres.2020.05.005_bb0015","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)","volume":"9","author":"Gringeri","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2020.05.005_bb0020","article-title":"Achieving the unimaginable: Health equity in haemophilia","author":"Skinner","year":"2019","journal-title":"Haemophilia."},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2020.05.005_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hae.13397","article-title":"Individualized PK-based prophylaxis in severe haemophilia","volume":"24","author":"Dargaud","year":"2018","journal-title":"Haemophilia."},{"key":"10.1016\/j.thromres.2020.05.005_bb0030","unstructured":"Comittee for medical products for human use, EMA, Guideline on the Investigation of Bioequivalence, CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/Corr **."},{"key":"10.1016\/j.thromres.2020.05.005_bb0035","series-title":"Draft Guidance for Industry on Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs\u2013General Considerations","author":"Food and Drug Administration","year":"2014"},{"issue":"4","key":"10.1016\/j.thromres.2020.05.005_bb0040","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/wics.1310","article-title":"Bioavailability and bioequivalence in drug development","volume":"6","author":"Chow","year":"2014","journal-title":"Wiley Interdiscip Rev Comput Stat."},{"key":"10.1016\/j.thromres.2020.05.005_bb0045","series-title":"Guideline on the Clinical Investigation of Recombinant and Human Plasma-derived Factor VIII Products","author":"Comittee for medical products for human use, EMA","year":"2018"},{"key":"10.1016\/j.thromres.2020.05.005_bb0050","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2006.01401.x","article-title":"In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting","volume":"13","author":"Bj\u00f6rkman","year":"2007","journal-title":"Haemophilia."},{"key":"10.1016\/j.thromres.2020.05.005_bb0055","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00228-009-0676-x","article-title":"Pharmacokinetics and dose requirements of factor VIII over the age range 3\u201374 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A","volume":"65","author":"Bj\u00f6rkman","year":"2009","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.thromres.2020.05.005_bb0060","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1055\/s-0038-1649902","volume":"74","author":"Prowse","year":"1995","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.05.005_bb0065","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1161\/01.CIR.56.4.605","article-title":"Prediction of the normal blood volume. Relation of blood volume to body habitus","volume":"56","author":"Feldschuh","year":"1977","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2020.05.005_bb0070","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3324\/haematol.2015.136275","article-title":"Math\u00f4t R;\u201cOPTI-CLOT\u201d study group. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients","volume":"101","author":"Hazendonk","year":"2016","journal-title":"Haematologica."},{"key":"10.1016\/j.thromres.2020.05.005_bb0075","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/hae.13251","article-title":"PK-guided personalized prophylaxis with Nuwiq(\u00ae) (human-cl rhFVIII) in adults with severe haemophilia A","volume":"23","author":"Lissitchkov","year":"2017","journal-title":"Haemophilia."},{"key":"10.1016\/j.thromres.2020.05.005_bb0080","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1538-7836.2008.03270.x","article-title":"Break-through bleed- ing in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A","volume":"7","author":"Collins","year":"2009","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.thromres.2020.05.005_bb0085","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2011-07-360594","article-title":"Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight","volume":"119","author":"Bj\u00f6rkman","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2020.05.005_bb0090","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/bcp.13858","article-title":"Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: using a limited sampling strategy in patients with severe haemophilia A","volume":"85","author":"Delavenne","year":"2019","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.thromres.2020.05.005_bb0095","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/hae.12905","article-title":"Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis","volume":"22","author":"Valentino","year":"2016","journal-title":"Haemophilia."},{"key":"10.1016\/j.thromres.2020.05.005_bb0100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2885.2004.00600.x","article-title":"Plasma terminal half-life","volume":"27","author":"Toutain","year":"2004","journal-title":"J Vet Pharmacol Ther."},{"key":"10.1016\/j.thromres.2020.05.005_bb0105","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2011-09-382846","article-title":"Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients","volume":"119","author":"Powell","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2020.05.005_bb0110","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.thromres.2020.05.005_bb0115","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.csda.2006.05.007","article-title":"Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model","volume":"51","author":"Samson","year":"2006","journal-title":"Comput Stat Data Anal"},{"key":"10.1016\/j.thromres.2020.05.005_bb0120","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A","volume":"11","author":"Tiede","year":"2013","journal-title":"J Thromb Haemost."},{"issue":"Suppl. 77","key":"10.1016\/j.thromres.2020.05.005_bb0125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/ejh.12500","article-title":"One-stage vs. chromogenic assays in haemophilia A","volume":"94","author":"Potgieter","year":"2015","journal-title":"Eur J Haematol."},{"issue":"4","key":"10.1016\/j.thromres.2020.05.005_bb0130","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2516.2010.02481.x","article-title":"International comparative field study of N8 evaluating factor VIII assay performance","volume":"17","author":"Viuff","year":"2011","journal-title":"Haemophilia."},{"key":"10.1016\/j.thromres.2020.05.005_bb0135","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jth.13867","article-title":"Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH","volume":"15","author":"Iorio","year":"2017","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.thromres.2020.05.005_bb0140","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/hae.13438","article-title":"Defining extended half-life rFVIII-A critical review of the evidence","volume":"24","author":"Mahlangu","year":"2018","journal-title":"Haemophilia."},{"key":"10.1016\/j.thromres.2020.05.005_bb0145","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/hae.13483","article-title":"Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII","volume":"24","author":"Hermans","year":"2018","journal-title":"Haemophilia."},{"key":"10.1016\/j.thromres.2020.05.005_bb0150","series-title":"Scientific and Standardization Committee Communication. The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors","article-title":"Scientific and standardization committee of the international society for thrombosis and haemostasis","author":"Lee","year":"2001"},{"issue":"7","key":"10.1016\/j.thromres.2020.05.005_bb0155","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/jth.14469","article-title":"Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: is there a difference?","volume":"17","author":"Carcao","year":"2019","journal-title":"J Thromb Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2020.05.005_bb0160","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.thromres.2020.05.005_bb0165","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.thromres.2020.05.005_bb0170","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00277-019-03747-2","article-title":"Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A","volume":"98","author":"Shah","year":"2019","journal-title":"Ann Hematol."},{"key":"10.1016\/j.thromres.2020.05.005_bb0175","article-title":"Favorable pharmacokinetic characteristics of extended-half-life recombinant factor VIII BAY 94-9027 enable robust individual profiling using a population pharmacokinetic approach [published online ahead of print, 2019 Nov 21]","author":"Solms","year":"2019","journal-title":"Clin Pharmacokinet."},{"issue":"4","key":"10.1016\/j.thromres.2020.05.005_bb0180","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jth.12506","article-title":"Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A","volume":"12","author":"Coyle","year":"2014","journal-title":"J Thromb Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2020.05.005_bb0185","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/rth2.12192","article-title":"Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: a randomized trial","volume":"3","author":"Escuriola Ettingshausen","year":"2019","journal-title":"Res Pract Thromb Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2020.05.005_bb0190","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1160\/TH16-12-0942","article-title":"Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates","volume":"117","author":"Iorio","year":"2017","journal-title":"Thromb Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2020.05.005_bb0195","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/hae.12887","article-title":"Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc","volume":"22","author":"Berntorp","year":"2016","journal-title":"Haemophilia."},{"issue":"7","key":"10.1016\/j.thromres.2020.05.005_bb0200","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/jth.14153","article-title":"Subcommittee on factor VIII, factor IX, and rare bleeding disorders. pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH","volume":"16","author":"Ragni","year":"2018","journal-title":"J Thromb Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2020.05.005_bb0205","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/jth.13662","article-title":"Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A","volume":"15","author":"Zhang","year":"2017","journal-title":"J Thromb Haemost."},{"issue":"9","key":"10.1016\/j.thromres.2020.05.005_bb0210","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-016-0492-2","article-title":"Improved pharmacokinetics with BAY 81-8973 versus antihemophilic factor (recombinant) plasma\/albumin-free method: a randomized pharmacokinetic study in patients with severe hemophilia A","volume":"56","author":"Shah","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.thromres.2020.05.005_bb0215","doi-asserted-by":"crossref","DOI":"10.1111\/hae.13973","article-title":"Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81-8973 from rFVIII-FS can continue their dosing schedule with improved protection [published online ahead of print, 2020 Apr 16]","author":"Solms","year":"2020","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.thromres.2020.05.005_bb0220","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2011-07-367003","article-title":"Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1\/2a study in hemophilia B patients","volume":"119","author":"Shapiro","year":"2012","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.thromres.2020.05.005_bb0225","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1111\/jth.13444","article-title":"Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B","volume":"14","author":"Zhang","year":"2016","journal-title":"J Thromb Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2020.05.005_bb0230","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/hae.13191","article-title":"Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials","volume":"23","author":"Tiede","year":"2017","journal-title":"Haemophilia."},{"issue":"12","key":"10.1016\/j.thromres.2020.05.005_bb0235","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1182\/blood-2012-05-429688","article-title":"Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients","volume":"120","author":"Santagostino","year":"2012","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.thromres.2020.05.005_bb0240","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1182\/blood-2011-02-335596","article-title":"Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B","volume":"118","author":"Negrier","year":"2011","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.thromres.2020.05.005_bb0245","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N Engl J Med."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820301687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820301687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:41:50Z","timestamp":1758735710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384820301687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":49,"alternative-id":["S0049384820301687"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2020.05.005","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics for haemophilia treaters: Meaning of PK parameters, interpretation pitfalls, and use in the clinic","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2020.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}